BioTuesdays

Tag - CELU

Celularity-Logo
Markets

HCW slashes Celularity PT on pipeline priority changes

H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...

January 30, 2023
Celularity
Markets

HCW starts Celularity at buy; PT $15

H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...

June 22, 2022